vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $164.7M, roughly 1.1× PTC THERAPEUTICS, INC.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -82.0%, a 129.9% gap on every dollar of revenue. On growth, BRC Group Holdings, Inc. posted the faster year-over-year revenue change (-21.9% vs -22.7%). Over the past eight quarters, PTC THERAPEUTICS, INC.'s revenue compounded faster (-11.5% CAGR vs -15.4%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
PTCT vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $188.3M |
| Net Profit | $-135.0M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | -43.3% | 32.3% |
| Net Margin | -82.0% | 47.9% |
| Revenue YoY | -22.7% | -21.9% |
| Net Profit YoY | -104.8% | 1710.8% |
| EPS (diluted) | $-1.63 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $164.7M | $188.3M | ||
| Q3 25 | $211.0M | $215.3M | ||
| Q2 25 | $178.9M | $188.2M | ||
| Q1 25 | $1.2B | $197.2M | ||
| Q4 24 | $213.2M | $241.0M | ||
| Q3 24 | $196.8M | $225.5M | ||
| Q2 24 | $186.7M | $256.0M | ||
| Q1 24 | $210.1M | $263.4M |
| Q4 25 | $-135.0M | $90.3M | ||
| Q3 25 | $15.9M | $91.1M | ||
| Q2 25 | $-64.8M | $139.5M | ||
| Q1 25 | $866.6M | $-10.0M | ||
| Q4 24 | $-65.9M | $-5.6M | ||
| Q3 24 | $-106.7M | $-284.4M | ||
| Q2 24 | $-99.2M | $-433.6M | ||
| Q1 24 | $-91.6M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | -43.3% | 32.3% | ||
| Q3 25 | 1.4% | 30.4% | ||
| Q2 25 | -19.5% | 5.7% | ||
| Q1 25 | 82.5% | -31.2% | ||
| Q4 24 | -76.2% | -69.2% | ||
| Q3 24 | -27.7% | -36.4% | ||
| Q2 24 | -21.5% | -90.8% | ||
| Q1 24 | -21.6% | -6.1% |
| Q4 25 | -82.0% | 47.9% | ||
| Q3 25 | 7.5% | 42.3% | ||
| Q2 25 | -36.3% | 74.1% | ||
| Q1 25 | 73.7% | -5.1% | ||
| Q4 24 | -30.9% | -2.3% | ||
| Q3 24 | -54.2% | -126.1% | ||
| Q2 24 | -53.1% | -169.4% | ||
| Q1 24 | -43.6% | -18.7% |
| Q4 25 | $-1.63 | $2.78 | ||
| Q3 25 | $0.20 | $2.91 | ||
| Q2 25 | $-0.83 | $4.50 | ||
| Q1 25 | $10.04 | $-0.39 | ||
| Q4 24 | $-0.85 | $-0.01 | ||
| Q3 24 | $-1.39 | $-9.39 | ||
| Q2 24 | $-1.29 | $-14.35 | ||
| Q1 24 | $-1.20 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $-205.3M | $-171.5M |
| Total Assets | $2.9B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | $226.6M | ||
| Q3 25 | $1.7B | $184.2M | ||
| Q2 25 | $2.0B | $267.4M | ||
| Q1 25 | $2.0B | $138.3M | ||
| Q4 24 | $1.1B | $146.9M | ||
| Q3 24 | $1.0B | $159.2M | ||
| Q2 24 | $1.1B | $236.9M | ||
| Q1 24 | $884.8M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-205.3M | $-171.5M | ||
| Q3 25 | $-155.8M | $-260.5M | ||
| Q2 25 | $-206.5M | $-351.7M | ||
| Q1 25 | $-185.8M | $-496.8M | ||
| Q4 24 | $-1.1B | $-488.2M | ||
| Q3 24 | $-1.1B | $-497.6M | ||
| Q2 24 | $-980.2M | $-218.3M | ||
| Q1 24 | $-893.9M | $228.4M |
| Q4 25 | $2.9B | $1.7B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | $2.7B | $1.5B | ||
| Q4 24 | $1.7B | $1.8B | ||
| Q3 24 | $1.8B | $2.2B | ||
| Q2 24 | $1.9B | $3.2B | ||
| Q1 24 | $1.8B | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $26.2M |
| Free Cash FlowOCF − Capex | $-36.6M | — |
| FCF MarginFCF / Revenue | -22.3% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | $26.2M | ||
| Q3 25 | $-66.3M | $-60.6M | ||
| Q2 25 | $-58.3M | $-25.6M | ||
| Q1 25 | $870.1M | $184.0K | ||
| Q4 24 | $-30.0M | $-2.7M | ||
| Q3 24 | $-77.0M | $19.5M | ||
| Q2 24 | $-71.5M | $111.5M | ||
| Q1 24 | $70.8M | $135.4M |
| Q4 25 | $-36.6M | — | ||
| Q3 25 | $-69.7M | — | ||
| Q2 25 | $-59.6M | — | ||
| Q1 25 | $868.4M | — | ||
| Q4 24 | $-33.8M | — | ||
| Q3 24 | $-77.5M | — | ||
| Q2 24 | $-78.8M | — | ||
| Q1 24 | $61.2M | — |
| Q4 25 | -22.3% | — | ||
| Q3 25 | -33.1% | — | ||
| Q2 25 | -33.3% | — | ||
| Q1 25 | 73.8% | — | ||
| Q4 24 | -15.8% | — | ||
| Q3 24 | -39.4% | — | ||
| Q2 24 | -42.2% | — | ||
| Q1 24 | 29.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 4.6% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | -4.17× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTCT
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
